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Introduction: The association between smoking-induced
chronic obstructive pulmonary disease (COPD) and lung cancer
(LC) is well documented. Recent genome-wide association
studies (GWAS) have identiﬁed 28 susceptibility loci for LC, 10
for COPD, 32 for smoking behavior, and 63 for pulmonary func-
tion, totaling 107 nonoverlapping loci. Given that common vari-
ants have been found to be associated with LC in genome-wide
association studies, exome sequencing of these high-priority
regions has great potential to identify novel rare causal variants.
Methods: To search for disease-causing rare germline muta-
tions, we used a variation of the extreme phenotype approach
to select 48 patients with sporadic LC who reported histories
of heavy smoking—37 of whom also exhibited carefully
documented severeCOPD(inwhomsmoking is considered the
overwhelming determinant)—and 54 unique familial LC cases
from families with at least three ﬁrst-degree relatives with LC
(who are likely enriched for genomic effects).
Results: By focusingonexomeproﬁles of the107 target loci,we
identiﬁed two key rare mutations. A heterozygous p.Arg696Cys
variant in the coiled-coil domain containing147 (CCDC147) gene
at 10q25.1was identiﬁed in one sporadic and two familial cases.
The minor allele frequency (MAF) of this variant in the 1000
Genomes database is 0.0026. The p.Val26Met variant in theJournal of Thoracic Oncology Vol. 11 No. 1: 52-61dopamine b-hydroxylase (DBH) gene at 9q34.2 was identiﬁed
in twosporadic cases; theminorallele frequencyof thismutation
is 0.0034 according to the 1000 Genomes database. We
also observed three suggestive rare mutations on 15q25.1:
iron-responsive element binding protein neuronal 2 (IREB2);
cholinergic receptor, nicotinic, alpha 5 (neuronal) (CHRNA5);
and cholinergic receptor, nicotinic, beta 4 (CHRNB4).
Conclusions: Our results demonstrated highly disruptive
risk-conferring CCDC147 and DBH mutations.
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Introduction
Chronic tobacco-induced airway inﬂammation pro-
vokes a milieu conducive to pulmonary carcinogenesis.
We and others have previously shown that tobacco-
induced chronic obstructive pulmonary disease
(COPD), which is also characterized by a sustained in-
ﬂammatory reaction in the airways and lung paren-
chyma, is a signiﬁcant contributor to risk for the
development of lung cancer (LC) in smokers.1 Likewise,
reduced pulmonary function is also reported as an
important variable when included in risk prediction
models.2 Recent genome-wide association studies
(GWAS) have identiﬁed 28 susceptibility loci for LC, 10
loci for COPD, 32 loci for smoking behavior (SM), and 63
loci for abnormal pulmonary function (PF) and related
phenotypes, totaling 107 unique GWAS susceptibility
loci (as of November 2014, Supplemental Table 1).
Interestingly, there is considerable overlap among the
susceptibility loci for these phenotypes. For example,
6p21.32 major histocompatibility class III region
(advanced glycosylation end product–speciﬁc receptor
[AGER]/mut S homolog 5 [MSH5i]), 15q24-25.1 cholin-
ergic receptor, nicotinic, alpha 5 (neuronal) (CHRNA3)/
cholinergic receptor, nicotinic, alpha 5 (neuronal)
(CHRNA5)/iron-responsive element binding protein
neuronal 2 (IREB2), and 19q13.2 cytochrome P450,
family 2, subfamily A, polypeptide 6 (CYP2A6) are shared
by all four phenotypes; 5p15.33 telomerase reverse
transcriptase (TERT)/CLPTMI-like (CLPTM1L)/aryl hy-
drocarbon receptor repressor (AHRR), 10q25.1 gluta-
thione S-transferase omega 2 (GSTO2)/vesicle transport
through interaction with t-SNAREs 1A (VTI1A), and
10q23.31 actin, alpha 2, smooth muscle, aorta (ACTA2)/
phospholipase C, epsilon 1 (PLCE1) are shared by three
of these phenotypes; and more than 15 loci are shared
by two of the four phenotypes (see Supplemental
Table 1). Therefore, LC and COPD are not discrete dis-
eases related only through smoking exposure; they may
also share genetic predisposition mechanisms.
Given the common variants that have been found to
be associated with LC in GWAS, exome sequencing with a
focused analysis provides a cost-effective approach for
further investigation of high-priority regions of the
genome and has great potential to identify rare causal
variants in GWAS loci, as targeted studies of inﬂamma-
tory bowel disease3 and hypertriglyceridemia4 havedemonstrated. Rare variants, with minor allele fre-
quencies (MAFs) less than 0.01 and modest to high effect
sizes,5–7 may play a crucial role in the etiology of com-
plex traits and could account for missing heritability that
is unexplained by common variants.
Our approach to unveiling these hidden rare variants
was to sequence selective cases of LC by adopting a
modiﬁed extreme phenotype approach. Only approxi-
mately 13% of cases of LC are reported as familial8;
however, individuals with a family history of LC are at an
approximately twofold to threefold higher risk for
development of the disease.9,10 Therefore, it could be
assumed that patients with LC who are from high-risk
families would tend to reﬂect the genetic component of
the etiology of LC more clearly than those who are not
from high-risk families. In the present study, to search
for the disease-causing rare germline mutations within
the target 107 GWAS loci, we selected (1) 48 patients
with sporadic LC who reported histories of heavy
smoking and 37 of whom exhibited carefully docu-
mented severe COPD (in which the environmental factor
of smoking is considered overwhelming), and (2) 54
unrelated unique patients with familial LC who were
from families with at least three ﬁrst-degree relatives
with LC (and who are likely enriched for genomic signal).
Methods
Study population
Study subjects with familial LC. Phenotype data and
biological specimens for 54 patients with LC who had
three or more ﬁrst-degree relatives affected with histo-
logically conﬁrmed LC were provided by the Genetic
Epidemiology of Lung Cancer Consortium (GELCC)
collection. Only one patient with LC per family was
included in the current study. The selection criteria
included availability of adequate amounts of good-quality
genomic DNA stored at the GELCC biorepository for
probands and for whom no DNA samples on other
affected family members were available. Samples and
data were collected by the familial LC recruitment sites of
the GELCC, which included the University of Cincinnati,
University of Colorado Health Science Center, Karmanos
Cancer Institute at Wayne State University, Louisiana
State University Health Sciences Center-New Orleans,
Mayo Clinic, University of Toledo, Johns Hopkins Uni-
versity, and Saccomanno Research Institute. The GELCC
study population and recruitment scheme have been
described in detail previously.11 COPD phenotype on
these patients with familial LC was not available.
Study subjects with sporadic LC. Forty-eight patients
with sporadic LC were selected from enrollees into an
ongoing study of COPD in current or former smokers
Figure 1. Workﬂow and annotation pipeline for the identiﬁ-
cation of candidate variants.
54 Liu et al Journal of Thoracic Oncology Vol. 11 No. 1that was launched in 2002.12–14 Ever-smokers older than
40 years were enrolled from three clinics within the
Texas Medical Center in Houston, Texas: Ben Taub
General Hospital, Houston Methodist Hospital, and
Michael E. DeBakey Veterans Affairs Medical Center. The
COPD phenotype was carefully deﬁned by irreversible
airﬂow limitation (reduced forced expiratory volume in
1 second <50% predicted and forced expiratory volume
in 1 second/forced vital capacity <0.7) assessed by
postbronchodilator spirometry. For this analysis, we
selected smokers enrolled in this study who had histo-
logically conﬁrmed LC. Information on family history of
LC was not available for these patients with sporadic LC.
DNA was isolated from the peripheral blood of the
patients with familial LC and those with sporadic LC. The
study was approved by the institutional review board of
all sites accruing participants and by the institutional
review board at the Baylor College of Medicine (BCM) for
exome sequencing conducted at the BCM Human
Genome Sequencing Center (HGSC).
Library preparation and capture enrichment
DNA samples were constructed into Illumina paired-
end precapture libraries according to the manufacturer’s
protocol (Illumina Multiplexing_SamplePrep_Guide_
1005361_D). The complete library and capture protocol,
as well as the oligonucleotide sequences, have been
described in detail previously.15 For exome capture, each
library pool was hybridized in solution to the BCM-
HGSC–designed VCRome 2.1 capture reagent according
to the manufacturer’s protocol (NimbleGen) with minor
revisions.
Exome sequencing, alignment, and variant
calling
The sequencing runs were performed in paired-end
mode using the Illumina HiSeq 2000 platform.
Sequence analysis was performed using the BCM-HGSC
Mercury analysis pipeline.16 All sequence reads were
mapped to the GRCh37 human reference genome using
the Burrows-Wheeler aligner.17 The resultant binary
alignment/map ﬁle was subjected to quality recalibra-
tion using Genome Analysis Toolkit.18 Putative variants,
including single-nucleotide variants (SNVs) and in-
sertions or deletions (Indels), were called using the
Atlas2 suite.19 Read qualities were recalibrated with
Genome Analysis Toolkit; a minimum quality score of 30
was required, and the variant had to have been present
in more than 15% of the reads covering the position.
Variant annotation and ﬁltering
This analysis was restricted to rare mutations map-
ping to the exons within the 107 selected regionsdescribed earlier (see Supplemental Table 1 for genomic
coordinates). Variants were annotated for effect on the
protein and predicted function using the Single-
Nucleotide Polymorphism (SNP) & Variation Suite
(SVS) software (Golden Helix, Inc.). This suite integrates
more than 378 databases for variant information
including the following: (1) MAF in the European
American population in the reference database (1000
Genomes [TG], Exome Sequencing Project [ESP] 6500)
and the University of California, Santa Cruz Common
SNPs 135/137/141 tracks, which include all variants
with a MAF of at least 0.01 in the general population; (2)
experimental evidence from disease variant databases
(such as the Catalogue of Somatic Mutations in Cancer
[COSMIC] and ClinVar); and (3) deleterious prediction of
variant function determined either by mutation type
(truncating, splicing, frame shift, stop gain/loss, or
exonic Indels) or mutation effects predicted by dbNSFP
Functional Predictions.
To generate a list of disease-causing candidate vari-
ants, we focused on identifying genes with rare and novel
variants (never reported in a publicly available database
or University of California, Santa Cruz All SNPs 135/137/
141 tracks) (Fig. 1). We used scaled C-scores from
the combined annotation-dependent depletion (CADD)
method20 for prioritization of causal variants. A C-score
of 10, 20, and 30, indicates variants predicted to be in the
top 10%, 1%, and 0.1% of the most deleterious in the
human genome, respectively.20 After implementing the
Table 1. Demographic and histologic characteristics of
patients with familial and sporadic lung cancer
Characteristics
Familial LC
(n ¼ 54)
Sporadic LCa
(n ¼ 48)
Age of diagnosis
Mean (SD) 56.0 (10.1) 60.9 (4.7)
Range 30–70 48–65
Sex
Male (%) 22 (40.0) 44 (91.7)
Female (%) 32 (60.0) 4 (8.3)
Smoking history
Ever-smoker (%) 46 (85.2) 48 (100)
Nonsmoker (%) 8 (14.8) 0 (0)
Cigarette pack-years
Mean (SD) 52.3 (30.8) 60.3 (30.9)
Range 0–165 14–150
Histologic characteristicsb
NSCLC 37 (86.0) 37 (90.5)
Adenocarcinoma 13 (30.2) 17 (40.5)
Squamous cell carcinoma 17 (39.5) 16 (38.1)
Large cell carcinoma 7 (16.3) 5 (11.9)
SCLC 6 (14.0) 4 (9.5)
aOf the patients in the 48 sporadic cases of LC, 37 also had severe
COPD.
bNumbers do not add up because of missing data.
LC, lung cancer; NSCLC, non–small cell lung cancer; SCLC, small
cell lung cancer.
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Browse (Golden Helix, Inc.) to visually conﬁrm the po-
tential candidate variants by rechecking the raw binary
alignment/map ﬁle data. We then tabulated the number
of candidate deleterious mutations per gene and within
our two study subgroups (familial versus sporadic) and
created a Venn diagram for the list of candidate variants
that were signiﬁcantly associated with the four different
phenotypes (LC, COPD, PF, and SM) in previous GWAS.
Sanger validation
The potential candidate variants were veriﬁed, and
segregation was examined by using Sanger capillary bidi-
rectional sequencing in the selected sample sites. Primers
speciﬁc to the region containing the variant to be tested
were designed, polymerase chain reactions (PCRs) were
prepared according to the Qiagen Multiplex PCR Kit pro-
tocol (Qiagen), and touchdown PCR was performed (all
PCR primers and conditions are available upon request).
SNVs were identiﬁed using SNP Detector and visually
displayed in Sequence Scanner v1.0 (Applied Biosystems).
Candidate variant protein annotation, structure
modeling, and protein-protein interaction
We used the online databases Pfam21 and PRINTS22 to
annotate and classify protein families and domains, the
BioGrid and the STRING23 for predicting protein-protein
interaction, and the PHYRE2 server24 for modeling the
3D structure of the candidate variant gene encoded-
protein. These resources use sequence-, structure-, and
systems biology–based features to predict whether the
mutation in the protein is likely to have a functional or
phenotypic effect.
Results
Demographic information, including age, sex, smok-
ing history, and histologic diagnosis, is summarized in
Table 1. All 54 unrelated patients with familial LC and 48
with sporadic LC were adult non-Hispanic whites. The
mean ages of onset of LC in the patients with familial and
sporadic LC were 56.0 and 60.9 years, respectively. More
than 85% of those with familial LC and all those with
sporadic LC (because of the study design criteria) re-
ported being ever-smokers, with mean pack-years of
52.3, and 60.3, respectively. Overall, non–small cell LC
had been diagnosed in 86.0% of those with familial LC
and 90.5% of those with sporadic LC. Adenocarcinoma
was diagnosed in 40.5% of those in the sporadic group
and 30.2% of those in the familial group for whom his-
tologic data were available.
Of 99,489 SNVs and 1206 Indels located in the exons of
the target 107 loci, our stepwise ﬁltering strategy identi-
ﬁed 39 potential candidate variants (see Fig. 1). Of these39 variants interrogated by Sanger sequencing, nine
mutations failed, and 30 variants (80%) were veriﬁed in
the original LC samples (Table 2). All the failed mutations
were singletons. Of the 30 veriﬁed candidate variants, ﬁve
variants were present in two or more patients, three
variants were located in highly likely functional sites
(CHRNA5 g.78880766 splice donor, myozenin 3 [MYOZ3]
g.150051315 splice acceptor, and chromosome 10 open
reading frame 11 [C10orf11] p.Ser8 frameshift), and three
SNVs were novel (patatin-like phospholipase domain
containing 8 [PNPLA8] p.Ile479Ser, pantothenate kinase 1
[PANK1] p.Phe163Ser, and insulin-degrading enzyme
[IDE] p.Asp9Asn) (see Table 2).
Overall, the total number and proportion of patients
with LC (N¼ 32) who carried these 30 candidate variants
were only slightly higher in the group with familial cases
(18 cases, 18/54 ¼ 33.3%) than in the group with spo-
radic cases (14 cases, 14/48¼ 29.2%, with 11 of these 14
patients also having severe COPD). The mean ages of the
familial and sporadic candidate mutation carriers were
not different from the overall means. In terms of smoking
intensity, however, carriers of familial mutations re-
ported fewer pack-years than their mean (43 versus 52),
whereas there was no difference in smoking intensity
among the carriers of sporadic mutations.
We identiﬁed two highly deleterious mutations
occurring inmore than three patients with LC (see Table 2
Table 2. List of 30 candidate deleterious germline mutations in familial and sporadic cases of lung cancer
Region Disease association Gene Markera SNV/Indels
Ref./
Alt. RS ID
MAF in
TG/ESP
CADD
C-scoreb
N mutated familial
vs. sporadic
Total N mutated
LC cases
10q25.1 LCþSMþPF CCDC147 10:106163533-SNV p.Arg696Cys C/T rs41291850 0.0026/0.0072 16.2 2 : 1 3
9q34.2 SM DBH 9:136501569-SNV p.Val26Met G/A rs76856960 0.0034/0.0045 17.3 0 : 2c 3
9:136522317-SNV p.Met563Thr T/C rs201973877 0.0002/0.0002 20.3 1 : 0
15q25.1 LCþSMþPFþCOPD IREB2 15:78783019-SNV p.Gly747Glu G/A rs139092247 0.0014/0.0034 35 1 : 0 3
CHRNA5 15:78880766-SNV g. splice donor G/A rs200616965 NA 22.7 0 : 1c,d
CHRNB4 15:78921343-SNV p.Ala435Val G/A rs56317523 0.0008/0.0028 27.2 1 : 0
16q23.1 PF KARS 16:75665388-SNV p.Arg421Gln C/T rs149772470 0.0002/0.0018 26.1 0 : 1c 3
16:75665146-SNV p.Arg448Cys G/A rs77573084 0.0006/0.0030 19.6 0 : 1c,d
WWOX 16:78466521-SNV p.Arg310Cys C/T rs193001955 0.0006/0.0006 24.1 0 : 1c
1q44 SM C1orf100 1:244541827-SNV p.Asp71His G/C rs41269385 0.0022/0.0065 14.2 2 : 0 2
2q35 PF TNS1 2:218686643-SNV p.Glu1027Val T/A rs112371945 0.0006/0.0013 22.7 1 : 0 2
2:218669288-SNV p.Thr1701Met G/A rs61740054 0.0010/0.0034 27.9 0 : 1c
5q32 LCþPF FBXO38 5:147817940-SNV p.Pro893Arg C/G rs141168806 NA/0.0001 22.9 1 : 0 2
5:147821690-SNV p.Val1108Ile G/A rs143682696 0.0002/0.0008 26.4 1 : 0
7q31.1 SM PNPLA8 7:108154659-SNV p.Cys379Gly A/C rs141089628 0.0002/0.0033 15.1 0 : 1c 2
7:108137944-SNV p.Ile479Ser A/C Novel NA 25.2 1 : 0
10q23.31 LCþSMþCOPD PANK1 10:91359156-SNV p.Phe163Ser A/G Novel NA 26.1 1 : 0 2
IDE 10:94243061-SNV p.Asp9Asn C/T Novel NA 36 0 : 1c,e
13q12.12 LC MIPEP 13:24448998-SNV p.Leu197Pro A/G rs150167906 0.0002/0.0023 21.4 1 : 1 2
14q22.1 PF NID2 14:52508948-SNV p.Thr567Met G/A rs150406341 0.0006/0.0060 19.3 1f : 1c,d 2
17q24.2 LCþPF BPTF 17:65889520-SNV p.Arg823Gln G/A rs375975293 NA/0.0001 19.8 1 : 0 2
17:65936627-SNV p.Thr2237Met C/T rs372551122 NA 17.2 0 : 1c
5q33.1 LCþPF MYOZ3 5:150051315-SNV g. splice acceptor A/G rs143036945 0.0002/0.0005 12.3 0 : 1 1
10q22.2-3 PF C10orf11 10:77542754-Deletion p.Ser8 Frameshift C/- rs146123023 0.007/0.0013 NA 1 : 0 1
12q13.3 PF LRP1 12:57577915-SNV p.Arg1993Trp C/T rs141826184 0.0004/0.0031 21.8 0 : 1c 1
12q21.2 SM NAV3 12:78392209-SNV p.Ser278Ile G/T rs755721519 NA 31 0 : 1c,e 1
14q24.2 PF SLC8A3 14:70515508-SNV p.Val152Met C/T rs144289733 0.0004/0.0008 27 1 : 0 1
15q15.2 LC TGM5 15:43527092-SNV p.Tyr502His A/G rs146901531 0.0002/0.0006 18.8 0 : 1c 1
18p11.3 LC LAMA1 18:6965341-SNV p.Arg2381Cys G/A rs142063208 0.0028/0.0016 25 1f : 0 1
19q13.2 LCþSMþPFþCOPD EGLN2 19:41307024-SNV p.Val183Met G/A rs117916638 0.0002/0.0004 16.9 1 : 0 1
aAll are heterozygous mutations.
bC-score is the overall measure of deleteriousness. C-score  20 indicates top 1% deleterious germline mutations in the human genome.
cSporadic LC patient(s) with severe COPD.
dEntries followed by superscript “d” refer to the same patient.
eEntries followed by superscript “e” refer to the same patient.
fEntries followed by superscript “f” refer to the same patient.
SNV, Single-nucleotide variants; Indels, insertions or deletions; Ref., reference; Alt., Alternative; RS ID, reference SNP ID number; MAF, minor allele frequency; TG/ESP, Egl-9 family hypoxia-
inducible factor 2; CADD, Combined Annotation-Dependent Depletion; LC, lung cancer; SM, smoking behavior; PF, pulmonary function; CCDC147, coiled-coil domain containing 147; DBH,
dopamine b-hydroxylase; COPD, chronic obstructive pulmonary disease; IREB2, iron-responsive element binding protein 2; CHRNA5, cholinergic receptor, nicotinic, alpha 5 (neuronal);
CHRNB4, cholinergic receptor, nicotinic, beta 4 (neuronal); KARS, lysyl-tRNA synthetase; WWOX, WW domain-containing oxidoreductase; C1ORF100, chromosome 1 open reading frame 100;
TNS1, tensin 1; FBXO38, F-box protein 38; PNPLA8, patatin-like phospholipase domain containing 8; PANK1, pantothenate kinase 1; IDE, insulin-degrading enzyme; MIPEP, mitochondrial in-
termediate peptidase;NID2, nidogen 2 (osteonidogen); BPTF, bromodomain PHD transcription factor;MYOZ3, myozenin 3; C10ORF11, chromosome 10 open reading frame 11; LRP1, low-density
lipoprotein receptor-related protein 1; NAV3, neuron navigator 3; SLC8A3, solute carrier family 8 (sodium/calcium exchanger), member 3; TGM5, transglutaminase 5; LAMA1, lamanin, alpha 1.
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January 2016 Rare Germline Mutations in Lung Cancer 57and Supplemental Fig. 1). The ﬁrst was a heterozygous
c.2086C>T in the coiled-coil domain-containing 147
gene (CCDC147, also called CFAP58), resulting in a
p.Arg696Cys substitution. This variant was identiﬁed in
two patients with familial LC (both women, mean age
54.5, mean pack-years 40, and squamous histologic fea-
tures) and one patient with sporadic LC (a 57-year-old
man, pack-years 88, with adenocarcinoma but without
COPD). Notably, the MAF of this variant is 0.0026 from
the TG, and 0.0072 from the ESP6500 databases. The
mutation is predicted to be protein damaging by
PolyPhen-2 (score: 1.0) and highly-functional by Muta-
tion taster. This variant has a high scaled CADDC-score of
16.2, which indicates that the Arg696 is predicted to be
in the top 10% possible deleterious substitutions in the
human genome. The CCDC147 spans 101kb, contains 18
exons, and has 872 amino acids (AAs) (Fig. 2); the
p.Arg696Cys is located in exon 14 and affects a strictly
evolutionarily conserved AA residue in the crystal
structure of tropomyosin (protein ID: Q5T655). This
p.Arg696Cys mutation is predicted to perturb the ter-
tiary structure (folding of the domain and stability of the
three-dimensional shape) of the protein because the
Cys696 forms a covalent bond disulﬁde bridge with
697Cys. It is also very close to the p.Arg698Gln, which is a
conﬁrmed somatic mutation in patients with cutaneous
melanoma shown from COSMIC database and the acety-
lation modiﬁcation site Lys692.
The second candidates were two missense SNVs,
p.Val26Met and p.Met563Thr, in the dopamine beta-
hydroxylase (DBH) gene (see Table 2 and Supplemental
Fig. 1). The p.Val26Met was found in two patients with
sporadic LC (both men, age 64 and 65, pack-years 40,
histologic diagnosis of adenocarcinoma with severe
COPD), and p.Met563Thr found in one patient with fa-
milial LC (a man, age 30, pack-years 52, histologic diag-
nosis not speciﬁed). The MAFs of these two variants were
0.0034/0.0045 and 0.0002/0.0002 from the TG/ESP6500
databases, respectively. The two mutations were pre-
dicted to be protein damaging by PolyPhen-2 (score 0.93
and 0.87), with CADD C-scores of 17.3 and 20.3, and they
exhibited extremely high degrees of sequence conserva-
tion (0.96 and 0.99, respectively). The DBH gene contains
12 exons, spans 23 kb, and has 617 AAs (protein ID:
P09172; see Fig. 2). The p.Val26Met is located within
exon 1, lies in the hydrophobic transmembrane region,
and possesses a helical structure. The p.Met563Thr
located in exon 11, and it lies in a highly conserved region
of a-helix and the dopamine b-monoxgenase (DBM) motif
IX that may inﬂuence the stability of the enzyme. This
somatic mutation is also reported in patients with acute
myeloid leukemia from the COSMIC database. These ob-
servations suggest that the two DBH mutations are likely
to have a detrimental effect on the protein.The other interesting candidates were three SNVs
located in the 15q25.1 loci: IREB2 p.Gly747Glu; CHRNA5
g.78880766 splice donor; and cholinergic receptor,
nicotinic, beta 4 (CHRNB4) p.Ala435Val. The CHRNA5
splicing variant found in a patient with sporadic LC (a
63-year-old man, 48 pack-years of smoking, non–small
cell LC, with severe COPD), who was also a carrier of
another two candidate mutations (nidogen 2 (osteoni-
dogen) [NID2] p.Thr567Met and lysyl-tRNA synthetase
[KARS] gene p.Arg448Cys); the IREB2 and CHRNB4 SNVs
were found in two patients with familial LC (both
women, ages 45 and 64, pack-years 45 and 80, with
small cell LC and unknown histologic diagnoses).
There were three additional candidate variants—
NID2 p.Thr567Met, mitochondrial intermediate pepti-
dase (MIPEP) p.Leu197Pro, and chromosome 1 open
reading frame 100 (C1orf100) p.Asp71His—that were
present in multiple LC cases. Other genes that harbored
multiple different mutations in different patients
included tensin 1 (TNS1), F-box protein 38 (FBXO38),
PNPLA8, KARS, and bromodomain PHD transcription
factor (BPTF). In addition, a patient with sporadic LC and
a history of extremely heavy smoking (a 65-year-old
man, 150 pack-years of smoking, adenocarcinoma, and
severe COPD) was a carrier of two novel mutations
with a CADD C-score higher than 30 (IDE p.Asp9Asn
and neuron navigator 3 [NAV3] p.Ser278Ile)
(see Table 2).
Of the 30 candidate variants belonging to 20 loci and
24 genes (Fig. 3A), seven genes (including CCDC147 and
DBH) had candidate variants observed both in those
with familial LC and in those with sporadic LC. Also (as
shown in Fig. 3B), among the candidate genes examined
in the current study, the CCDC147, IREB2/CHRNA5/
CHRNB4, PANK1/IDE, and egl-9 family hypoxia-inducible
factor 2 (EGLN2) genes were shared by three or more
phenotypes (LC, COPD, PF, and SM) from the previously
published GWAS (see Table 2 and Fig. 3B).
Discussion
Despite previous family-based linkage studies,
intensive population-based GWAS analyses, and candi-
date gene screening, a large proportion of the heritability
of LC remains unexplained. Using an extreme phenotype
design, this report describes the ﬁrst exome sequencing
approach comparing heavy smokers with familial and
sporadic LC and evaluating the effects of rare coding
variation in the GWAS loci associated with LC, COPD, SM,
and PF. Our results showed that the familial mutation
carriers reported fewer pack-years than their group’s
mean (43 versus 52), whereas there was no difference in
smoking intensity among the sporadic carriers.
Furthermore, we identiﬁed two disease-causing rare
mutations on 10q25.1 (CCDC147 p.Arg696Cys) and
Figure 2. Chromosomal position, gene structure, protein domain(s), and sequence of the candidate mutations of coiled-coil
domain containing 147 (CCDC147I) and dopamine b-hydroxylase (DBH) genes. The mutations were conﬁrmed with Sanger
sequencing and are indicated with red arrows. CCDC147 includes two coiled coil regions: 106-595 AA and 642-839 AA. DBH
consist of ﬁve domains: transmembrane (20-37 AA), DOMON (dopamine b-monooxygenase N-terminal; 56-172 AA), Cu2_N
(copper type II, N-terminal; 213-341 AA), Cu2_C (copper type II, C-terminal; 360-524 AA), and dopamine b-monooxygenase
motif IX; 552-572 AA).
58 Liu et al Journal of Thoracic Oncology Vol. 11 No. 19q34.2 (DBH p.Val26Met and p.Met563Thr), and three
suggestive rare mutations on 15q25.1 (IREB2 p.Gly747-
Glu, CHRNA5 g.78880766 splice donor, and CHRNB4
p.Ala435Val), although the ﬁndings require replication.Patients with familial LC and patients with sporadic LC
are indistinguishable at initial clinical examination, and
our results demonstrated that the two forms of LC may
have both shared determinants and distinct components.
Figure 3. Venn diagrams and schematic representations of
all genes with candidate mutations in the familial and spo-
radic lung cancer groups. (A) Shared and speciﬁc genes with
candidate deleterious variants in the familial, sporadic, or
both lung cancer groups. (B) The list of genes with candidate
deleterious variants that were signiﬁcantly associated with
these four different phenotypes in previous genome-wide
association studies.
January 2016 Rare Germline Mutations in Lung Cancer 59Strong evidence for an LC-conferring deleterious mu-
tation was observed at CCDC147 p.Arg696Cys in three pa-
tients with LC (two with familial LC and one with sporadic
LC). Interestingly, the two familial carriers were lighter
smokers and had an earlier age of onset than the overall
mean for familial cases. The sporadic carrier was a heavier
smokerwith a history of 88 pack-years and nodocumented
COPD. Although several genes in 10q25.1 loci have been
implicated in susceptibility to LC,25 PF,26 and SM27 in
GWAS, very little is known about the function of the
CCDC147 gene in humans or mice, although it is thought to
produce a functional protein asdescribed in theProteomics
database. CCDC147 protein, which is also known as cilia-
and ﬂagella-associated protein 58 (CFAP58), demonstrates
high expression in T cells, nasal epithelium, lungs, and
alveolar ﬂuids (http://www.genecards.org/cgi-bin/
carddisp.pl?gene¼CFAP58). It is believed to interact
with members of the shelterin complex, the human telo-
mere repeat binding factor 1 (TRF1) and protection of
telomeres 1 (POT1), as reported in the BioGRID database
and STRING Interaction Network. Interestingly, recent
studies have shown that rare mutations in the gene POT1
are associated with chronic lymphocytic leukemia,28
familial melanoma,29 and familial glioma,30 in which it is
thought to result in telomere deprotection and length
extension associated with cancer. Furthermore, one of the
most important functions of shelterin includes modulation
of telomerase activity, which has been detected in
approximately 85% of cancers and is linked to genomic
instability and tumorigenesis. Although direct evidence
regarding the biological function of CCDC147 is lacking,
our ﬁnding of CCDC147 as a novel telomere-interacting
protein underscores the need for future work that could
elucidate the role of this gene in LC pathogenesis.
Another main ﬁnding was the highly disruptive and
deleterious rare mutations on 9q34.2 DBH, p.Val26Met
and p.Met563Thr, in three patients with LC (one with
familial LC and two with sporadic LC). The familial car-
rier was very young (age 30). Both sporadic carriers had
adenocarcinoma and severe COPD. Previous GWAS
identiﬁed DBH rs3025343 as a locus associated with
SM.31 The DBH (OMIM 609312) gene contributes pri-
marily to conversion of dopamine to noradrenaline.
Dopamine is known to be released from neurons in
response to nicotine and plays a well-documented role in
determining an individual’s predisposition to nicotine
dependence through its role in mediating drug reward in
the brain.31–34 The contribution of cigarette smoking to
both LC and COPD could invoke a variety of underlying
biological processes, including inﬂammation, epithelial-
mesenchymal transition, oxidative stress, DNA repair,
and abnormal cellular proliferation.
NID2 is a known GWAS hit for PF35 and blood lipid
phenotypes36 and a new biomarker for ovarian cancer,37hepatocellular carcinoma,38 and oral squamous cell
carcinoma.39 NID2 (OMIM 605399) encodes a member
of the highly conserved nidogen family of basement
membrane proteins. This protein binds collagens I and
IV and laminin, is involved in stabilizing and maintaining
the structure of the basement membrane, and plays a
key role in the cell-extracellular matrix. Unbalanced
proteolysis in the extracellular matrix is a potential
mechanism to explain inﬂammatory processes within
the emphysematous lung. NID2mutation in patients with
LC may be conducive to invasion and metastasis of
tumor cells by loosening cell interaction with basal
membrane and weakening the strength of the basement
membrane itself, and it could be a marker of progression
as well.
60 Liu et al Journal of Thoracic Oncology Vol. 11 No. 1A main strength of this study is its focus on patients
with extreme phenotypes, who are the most likely to be
informative. For quantitative traits, one can select in-
dividuals with extreme trait values after adjusting for
known covariates. Alternatively, in disease-focused
studies, selection of individuals with extreme pheno-
types can be conducted on the basis of known risk factors.
Smoking, family history of LC, and COPD are all well-
documented risk factors for LC. Because the frequencies
of alleles that contribute to the trait/disease are enriched
in phenotype extremes (such as familial LC or patients
with both LC and COPD), studying extremes has been
shown to provide more than ﬁve times the power (only
20% of the subjects compared with in traditional de-
signs).7 In the present study, the recurrent rare muta-
tions described herein suggest that it may be possible to
identify susceptibility genes in a relatively small sample
size, although we cannot rule out the possibility that the
results have been observed by chance. The small sample
size and lack of validation of the identiﬁed mutations in a
separate large-scale cohort limit the relevance of our
ﬁndings. Another limitation of this analysis is phenotype
misclassiﬁcation between familial and sporadic LC. For
the patients with familial LC, we lacked COPD phenotype
data, and for those with sporadic LC, family history of LC
was not available. Also, we acknowledge the existence of
a sex imbalance between the familial and sporadic cases
that could cause bias and limit applicability of the ﬁnd-
ings to the general population.
In summary, our results demonstrated highly dis-
ruptive germline mutations in the genes CCDC147 and
DBH in patientswith LC that are interesting candidates for
LC risk alleles. The overlap in risk loci between familial
and sporadic LC, and that between COPD and LC, may be
due to genes and mutations involving telomere mainte-
nance, to inﬂammation, or to the lack of family history in
the sporadic cases being the result of no smoking exposure
in other carriers of the mutation in their families. There-
fore, going forward, comprehensive genomic analyses of
whole genomes (from point mutations to large structural
variants) and a large number of LC samples from diverse
race/ethnic groups for validation, as well as further
functional works for the top two candidate genes, will be
needed to better understand the underlying molecular
genetics and guide screening for mutations in this unique
subset of patients to assess their potential risk for LC.
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Web resources
GWAS, Genome-wide Association Studies Catalog,
www.genome.gov/gwastudies/
TG, Thousand Genomes, http://www.1000genomes.
org
ESP, Exome Sequencing Project, http://evs.gs.
washington.edu/EVS/
COSMIC, Catalogue of Somatic Mutations in Cancer,
http://cancer.sanger.ac.uk/cosmic
OMIM, Online Mendelian Inheritance in Man, http://
www.omim.org
CADD, Combined Annotation Dependent Depletion,
cadd.gs.washington.edu/
Pfam, http://pfam.janelia.org/
PRINTS, protein motif ﬁngerprint database, http://
www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/
BioGRID, Biological General Repository for Interac-
tion Datasets, http://www.thebiogrid.org
STRING, Search Tool for the Retrieval of Interacting
Genes, http://string-db.org/
Phyre2, www.sbg.bio.ic.ac.uk/phyre2/
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